Yesterday, November 11, Alnylam Pharmaceuticals (NASDAQ: ALNY) and The Medicines Company (NASDAQ: MDCO) reported ALN-PCSsc Phase I data during a late-breaker session at the American Heart Association (AHA) meeting held in Orlando.

The additional data in healthy volunteers with elevated LDL-C further supported the potential for a bi-annual dosing regimen with a least square mean (LSM) percentage reduction of LDL-C of 47%, 180 days following a 300 mg single administration of ALN-PCSsc. The therapy continues to be well tolerated and achieved LDL-C lowering competitive with currently approved monoclonal antibodies (MAbs).

FBR Capial analyst, Christopher James, believes the potential for bi-annual dosing, the potent lowering of LDLC, and the safe profile support a potential best-in-class profile for the treatment of hypercholesterolemia.

No change to Outperform rating or $180PT.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $104.29 yesterday.